Conversely, Gonugunta et al (2017), also provided proof of principle evidence that blocking STING degradation to boost STING signalling can also be exploited for therapeutic benefit, by demonstrating that co‐administration of cGAMP and the lysosomal inhibitor, Bafilomycin A1, improved tumour clearance over cGAMP alone in a murine melanoma model. This evidence concerns the gene STING1 and melanoma.